Erratum to: T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Mahmoud H. Mosli · Jesus Rivera-Nieves ·
Brian G. Feagan

Published online: 19 February 2014
© Springer International Publishing Switzerland 2014

Erratum to: Drugs
DOI 10.1007/s40265-013-0176-2

Section 3.1.6.1 Efalizumab. Last sentence, which previously read:

However, the development of PML in three etrolizumab-treated patients with psoriasis resulted in the drug being withdrawn from the market in 2009.

Should read:

However, the development of PML in three efalizumab-treated patients with psoriasis resulted in the drug being withdrawn from the market in 2009.

The online version of the original article can be found under doi:[10.1007/s40265-013-0176-2](https://doi.org/10.1007/s40265-013-0176-2).

M. H. Mosli · B. G. Feagan (✉)
Department of Medicine, University of Western Ontario,
100 Perth Dr, London, ON N6A 5K8, Canada
e-mail: Brian.Feagan@RobartsInc.com

M. H. Mosli
Department of Medicine, King Abdulaziz University,
Jeddah, Saudi Arabia

M. H. Mosli · B. G. Feagan
Robarts Clinical Trials Inc, Robarts Research Institute,
University of Western Ontario, 100 Perth Dr, London,
ON N6A 5K8, Canada

J. Rivera-Nieves
Department of Medicine, Division of Gastroenterology,
Inflammatory Bowel Disease Center, University of California,
San Diego, USA